# A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

> **NCT06056297** · PHASE3 · RECRUITING · sponsor: **X4 Pharmaceuticals** · enrollment: 176 (estimated)

## Conditions studied

- Neutropenia

## Interventions

- **DRUG:** Mavorixafor
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06056297
- **Lead sponsor:** X4 Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-06
- **Primary completion:** 2027-09
- **Final completion:** 2027-11
- **Target enrollment:** 176 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06056297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06056297, "A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06056297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*